Table 2 Updates on survival for HIV-associated lymphoma
From: HIV associated lymphoma: latest updates from 2023 ASH annual meeting
Author | Study Type | Regimen | Patients | ORR | CR | Survival | References |
|---|---|---|---|---|---|---|---|
Bryan Valcarcel | Retrospective | R-CHOP | DLBCL, N = 1030 | -- | -- | 5-year OS: 45%-53% | [3] |
Kathryn Kline | Retrospective | Chemotherapy and/or monoclonal anti bodies | HIV-assosiated lymphoma, N = 181 | -- | -- | 2-year OS: | [4] |
(DLBCL, N = 83; HL, N = 32; PCNSL, N = 9; | 41%(2000–2013); | ||||||
BL, N = 31; PEL, N = 2; PBL, N = 9;Other, N = 15 | 50%(2014–2021) | ||||||
Maria Huguet | Retrospective | ABVD | HL, N = 19 | -- | -- | 5-year OS: 93% | [5] |
(monocyte count < 0.6 x10^9/LV) | |||||||
Kathryn Lurain | Retrospective | PD-1 | HL, N = 23 | 83% | 70% | Median OS: 23.6 months | [6] |